Integra Lifesciences Holdings Corp to Post Q2 2018 Earnings of $0.58 Per Share, Jefferies Group Forecasts (IART)
Integra Lifesciences Holdings Corp (NASDAQ:IART) – Research analysts at Jefferies Group raised their Q2 2018 earnings estimates for shares of Integra Lifesciences in a research note issued to investors on Tuesday. Jefferies Group analyst R. Denhoy now forecasts that the life sciences company will earn $0.58 per share for the quarter, up from their previous estimate of $0.57. Jefferies Group has a “Buy” rating and a $63.00 price target on the stock. Jefferies Group also issued estimates for Integra Lifesciences’ Q2 2019 earnings at $0.68 EPS, Q4 2019 earnings at $0.75 EPS, FY2020 earnings at $3.08 EPS, FY2021 earnings at $3.53 EPS and FY2022 earnings at $4.02 EPS.
Integra Lifesciences (NASDAQ:IART) last released its quarterly earnings data on Tuesday, February 27th. The life sciences company reported $0.64 EPS for the quarter, beating the Zacks’ consensus estimate of $0.56 by $0.08. Integra Lifesciences had a net margin of 5.45% and a return on equity of 17.30%. The business had revenue of $368.60 million during the quarter, compared to analysts’ expectations of $362.64 million. During the same quarter in the prior year, the company earned $0.52 EPS. The firm’s quarterly revenue was up 44.2% on a year-over-year basis.
Shares of Integra Lifesciences (NASDAQ:IART) opened at $52.70 on Thursday. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.49 and a quick ratio of 3.39. Integra Lifesciences has a 1 year low of $40.51 and a 1 year high of $56.42. The company has a market cap of $4,059.72, a price-to-earnings ratio of 26.80, a P/E/G ratio of 1.62 and a beta of 0.65.
In other Integra Lifesciences news, Director Keith Bradley sold 15,658 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $55.00, for a total transaction of $861,190.00. Following the completion of the transaction, the director now owns 37,074 shares in the company, valued at approximately $2,039,070. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 21.50% of the stock is currently owned by corporate insiders.
Hedge funds and other institutional investors have recently made changes to their positions in the company. Prudential Financial Inc. grew its holdings in shares of Integra Lifesciences by 3.3% in the 3rd quarter. Prudential Financial Inc. now owns 105,836 shares of the life sciences company’s stock valued at $5,343,000 after acquiring an additional 3,340 shares in the last quarter. Jennison Associates LLC grew its holdings in shares of Integra Lifesciences by 48.3% in the 3rd quarter. Jennison Associates LLC now owns 1,034,702 shares of the life sciences company’s stock valued at $52,232,000 after acquiring an additional 336,930 shares in the last quarter. First Trust Advisors LP grew its holdings in shares of Integra Lifesciences by 216.1% in the 3rd quarter. First Trust Advisors LP now owns 51,084 shares of the life sciences company’s stock valued at $2,579,000 after acquiring an additional 34,925 shares in the last quarter. Engineers Gate Manager LP bought a new position in shares of Integra Lifesciences in the 4th quarter valued at about $1,942,000. Finally, Magnetar Financial LLC bought a new position in shares of Integra Lifesciences in the 3rd quarter valued at about $538,000. Institutional investors own 86.39% of the company’s stock.
TRADEMARK VIOLATION WARNING: This report was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.dailypolitical.com/2018/03/03/integra-lifesciences-holdings-corp-to-post-q2-2018-earnings-of-0-58-per-share-jefferies-group-forecasts-iart.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.